Combination therapy shows enhanced inhibition of cell viability in CRPC models, suggesting effective treatment options.
Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.
No takes yet. Share an insight, caveat, or question.
Brim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: